Page last updated: 2024-08-21

pyrazines and Osteolysis

pyrazines has been researched along with Osteolysis in 23 studies

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (34.78)29.6817
2010's15 (65.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S1
Bakhous, A; Waheed, S; Zhu, H1
Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K1
Bokhari, SW; Jones, FM1
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ1
Ise, M; Kumagai, K; Sakai, C; Tsujimura, H1
Azadeh, N; Fonseca, R; Kelemen, K1
Khan, S; Li, X; Ling, W; Pennisi, A; Yaccoby, S; Zangari, M1
Drake, MT; Rajkumar, SV1
Roodman, GD2
Arts, J; Coulton, L; Croucher, P; De Raeve, H; Deleu, S; Lemaire, M; Menu, E; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K1
Aoki, K; Eda, H; Kato, S; Marumo, K; Ohkawa, K; Okawa, Y; Takada, K; Tanaka, T1
Abildgaard, N; Delaissé, JM; Garnero, P; Lund, T; Ormstrup, T; Pedersen, PT; Plesner, T; Søe, K1
Ayers, DC; Barthel, TK; Bouxsein, ML; Cheng, D; Hussain, S; Jones, MD; Lian, JB; Liu, JC; Lovria, E; Mukherjee, S; Mulay, S; Schoonmaker, JA; Stein, GS1
Adam, Z; Hájek, R; Jakubcová, R; Klincová, M; Krejcí, M; Mayer, J; Pour, L; Szturz, P; Zahradová, L1
Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B1
Cheng, T; Mao, X; Pan, X; Zhang, X1
Cheng, T; Mao, X; Pan, X; Peng, X; Zhang, X; Zhao, S1
Brunton, VG; Idris, AI; Logan, JG; Marino, S; Muir, M; Sophocleous, A1
Mundy, GR; Oyajobi, BO1
Dimopoulos, MA; Rahemtulla, A; Terpos, E1
Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Müller, C; Schulz, CO; Sezer, O; Zavrski, I1

Reviews

2 review(s) available for pyrazines and Osteolysis

ArticleYear
Pathogenesis of myeloma bone disease.
    Leukemia, 2009, Volume: 23, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Denosumab; Fractures, Spontaneous; Glucocorticoids; Humans; Hypercalcemia; Immunologic Factors; Interleukins; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteoclasts; Osteolysis; Pyrazines; RANK Ligand; Stromal Cells; Wnt Proteins

2009
Current treatment options for myeloma.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine

2005

Trials

2 trial(s) available for pyrazines and Osteolysis

ArticleYear
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
    European journal of haematology, 2010, Volume: 85, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Pyrazines

2010
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
    European journal of haematology, 2006, Volume: 77, Issue:3

    Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Middle Aged; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteolysis; Protease Inhibitors; Pyrazines

2006

Other Studies

19 other study(ies) available for pyrazines and Osteolysis

ArticleYear
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10

    Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine

2013
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid

2013
Myeloma presenting during pregnancy.
    Hematological oncology, 2014, Volume: 32, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous

2014
Hyperammonemic encephalopathy in multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid

2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib

2014
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms

2014
Amitriptyline-induced agranulocytosis with bone marrow confirmation.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Agranulocytosis; Amitriptyline; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Febrile Neutropenia; Female; Filgrastim; Fractures, Spontaneous; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multiple Myeloma; Osteolysis; Peripheral Nervous System Diseases; Pyrazines; Recombinant Proteins; Urinary Tract Infections

2014
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    American journal of hematology, 2009, Volume: 84, Issue:1

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Development; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Protease Inhibitors; Pyrazines; Rabbits

2009
Effects of bortezomib on bone disease in multiple myeloma.
    American journal of hematology, 2009, Volume: 84, Issue:1

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoclasts; Osteolysis; Pyrazines

2009
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
    Cancer research, 2009, Jul-01, Volume: 69, Issue:13

    Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Disease Models, Animal; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Myeloma; Neovascularization, Pathologic; Osteolysis; Pyrazines

2009
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
    European journal of haematology, 2010, Volume: 85, Issue:1

    Topics: 3T3 Cells; Acyltransferases; Animals; Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; DNA Primers; Fibroblast Growth Factor 2; Humans; Mice; Models, Biological; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; RNA, Messenger; Transcription Factors

2010
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Osteolysis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiopharmaceuticals; Xenograft Model Antitumor Assays

2010
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2011, Volume: 24, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clodronic Acid; Femur; Humans; Male; Multiple Myeloma; Osteolysis; Pyrazines; Radiography; Recurrence; Remission Induction

2011
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-01, Volume: 17, Issue:23

    Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2011
Therapeutic potential of the proteasome inhibitor Bortezomib on titanium particle-induced inflammation in a murine model.
    Inflammation, 2012, Volume: 35, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Female; I-kappa B Kinase; Inflammation; Inflammation Mediators; Joint Prosthesis; Mice; Mice, Inbred BALB C; NF-kappa B; Osteolysis; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; Titanium; Tumor Necrosis Factor-alpha

2012
Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.
    Inflammation, 2012, Volume: 35, Issue:4

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Arthroplasty, Replacement; Boronic Acids; Bortezomib; Female; Inflammation; Mice; Mice, Inbred BALB C; Osteolysis; Osteoprotegerin; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; RANK Ligand; Titanium; TNF Receptor-Associated Factor 6; Vascular Endothelial Growth Factors

2012
Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:5

    Topics: Animals; Bone Remodeling; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Imidazoles; Mice; Osteoclasts; Osteolysis; Protein-Tyrosine Kinases; Pyrazines; Receptor, IGF Type 1

2013
Role of the bone marrow microenvironment in multiple myeloma.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:11

    Topics: Adjuvants, Immunologic; Bone and Bones; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Cell Division; Chemokine CCL3; Chemokine CCL4; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Multiple Myeloma; Osteoclasts; Osteolysis; Osteoprotegerin; Protease Inhibitors; Protein Prenylation; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl

    Topics: Animals; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Carrier Proteins; Chemokine CCL3; Chemokine CCL4; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Glycoproteins; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Mice; Multienzyme Complexes; Multiple Myeloma; Osteolysis; Osteoprotegerin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor

2003